Bell Investment Advisors Inc Raises Position in Abbott Laboratories $ABT

Bell Investment Advisors Inc boosted its position in Abbott Laboratories (NYSE:ABT) by 57.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,764 shares of the healthcare product maker’s stock after purchasing an additional 1,013 shares during the period. Bell Investment Advisors Inc’s holdings in Abbott Laboratories were worth $376,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of ABT. Brighton Jones LLC increased its stake in shares of Abbott Laboratories by 10.1% in the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after purchasing an additional 4,755 shares in the last quarter. St. Louis Trust Co boosted its holdings in Abbott Laboratories by 21.7% in the 1st quarter. St. Louis Trust Co now owns 9,679 shares of the healthcare product maker’s stock worth $1,284,000 after buying an additional 1,723 shares during the period. Csenge Advisory Group grew its stake in Abbott Laboratories by 21.0% in the 1st quarter. Csenge Advisory Group now owns 19,307 shares of the healthcare product maker’s stock valued at $2,529,000 after buying an additional 3,356 shares in the last quarter. Brogan Financial Inc. raised its holdings in Abbott Laboratories by 7.3% during the 1st quarter. Brogan Financial Inc. now owns 3,215 shares of the healthcare product maker’s stock valued at $426,000 after acquiring an additional 218 shares during the period. Finally, SNS Financial Group LLC lifted its position in shares of Abbott Laboratories by 0.7% during the first quarter. SNS Financial Group LLC now owns 12,591 shares of the healthcare product maker’s stock worth $1,670,000 after acquiring an additional 83 shares in the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories Stock Up 1.0%

ABT stock opened at $130.59 on Friday. The company’s 50 day moving average is $130.38 and its 200 day moving average is $131.35. The stock has a market cap of $227.08 billion, a price-to-earnings ratio of 16.36, a price-to-earnings-growth ratio of 2.36 and a beta of 0.68. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25. Abbott Laboratories has a 1-year low of $110.86 and a 1-year high of $141.23.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.30. The business had revenue of $11.37 billion during the quarter, compared to analyst estimates of $11.40 billion. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.78%. Abbott Laboratories’s revenue for the quarter was up 6.9% on a year-over-year basis. During the same period in the previous year, the business posted $1.21 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. Sell-side analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be paid a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date of this dividend is Wednesday, October 15th. Abbott Laboratories’s dividend payout ratio is currently 29.57%.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on ABT. Raymond James Financial boosted their price objective on Abbott Laboratories from $141.00 to $146.00 and gave the company an “outperform” rating in a research note on Thursday, October 16th. Daiwa Capital Markets lifted their target price on Abbott Laboratories from $134.00 to $136.00 and gave the company an “outperform” rating in a report on Tuesday, October 21st. BTIG Research reissued a “buy” rating and issued a $145.00 price target on shares of Abbott Laboratories in a report on Wednesday, October 15th. Benchmark assumed coverage on shares of Abbott Laboratories in a research note on Friday, October 10th. They set a “buy” rating and a $145.00 price objective for the company. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $147.00 target price on shares of Abbott Laboratories in a research note on Thursday, October 16th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, Abbott Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $147.00.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.